Liability Related to the Sale of Future Royalties- Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Oct. 19, 2021 USD ($)
Deferred Revenue Arrangement [Line Items]
Proceeds from sale of future royalties, gross	$ 50,000,000.0
Royalty issuance cost	2,500,000
Derivative liability	$ 802,000
Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of annual net revenues	14.00%
Minimum [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of annual net revenues	1.50%
HCR [Member]
Deferred Revenue Arrangement [Line Items]
Purchase price	$ 125,000,000.0
Initial investment amount	$ 13,500		$ 50,000,000.0
Description of net investment hedge activity	Under the Revenue Interest Agreement, HCR is entitled to receive tiered royalties on: (i) worldwide net sales of Included Products (as defined below) by the Company (and excluding sales by licensees), and (ii) any payments received by licensees, in each case of tebipenem HBr, SPR720, SPR206 and any other products marketed by the Company (the “Included Products”) in amounts ranging from 12% to 1% based on annual net revenues (or 14% to 1.5% if the Third Investment Amount is funded). The applicable royalty rate is subject to a step-down if certain sales milestones are met. When HCR has received aggregate payments equal to 250% of the Investment Amount (the “Hard Cap”), HCR’s right to receive royalties on Net Revenues will terminate. The Hard Cap will be $250 million upon tebipenem HBr approval, or $312.5 million if the Third Investment Amount is funded. If the Company has not received FDA approval for tebipenem HBr for a cUTI indication on or prior to December 31, 2022, the Revenue Interest Agreement will terminate and the Company will pay to HCR, no later than January 15, 2023, an amount equal to the Initial Investment Amount plus interest equal to an annual 13.5% rate of return. If HCR has not received aggregate payments of at least 60% of the Investment Amount by September 30, 2025 and at least 100% of the Investment Amount by September 30, 2027 (each, a “Minimum Amount”), then the Company will be obligated to make a cash payment to HCR in an amount sufficient to gross HCR up to the applicable Minimum Amount.
Hard capital amount	$ 250,000,000
Investment amount funded	$ 312,500,000
Percent of aggregate payment received	250.00%
Percent of minimum aggregate payment received	1
Date Of Minimum Aggregate Payment Received Threshold	Sep. 30, 2027
Proceeds from sale of future royalties, gross	$ 50,000,000
Royalty issuance cost	(2,460,000)
Derivative liability	$ 1,006,000
Effective interest rate	20.80%
Percentage of conditional obligation in case of default	2.50
HCR [Member] | Forecast [Member]
Deferred Revenue Arrangement [Line Items]
Additional investment amount		$ 50,000,000.0
Alternative investment		$ 25,000,000.0
HCR [Member] | Maximum [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of annual net revenues	12.00%
HCR [Member] | Minimum [Member]
Deferred Revenue Arrangement [Line Items]
Percentage of annual net revenues	1.00%
Percent of minimum aggregate payment received	0.60
Date Of Minimum Aggregate Payment Received Threshold	Sep. 30, 2025